Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in
high risk patients was considered a "standard" method to prevent PEP. However, the risk
factors of PEP is not fully clear. Rectal indomethacin before ERCP for all patients, not just
for selected high-risk patients, may preventing PEP maximum. The purpose of this study is to
determine whether routine using of rectal indomethacin is more effective than the conditional
strategy.
Phase:
N/A
Details
Lead Sponsor:
Air Force Military Medical University, China Fourth Military Medical University